For instance, by transfection with pGEG.mIL-12 and pGEG.mIL-18 plasmids by means of EBV/lipoplex, the engineered B16 melanoma vaccine could secrete approximately 10 times higher level of related cytokines than transfection with pG.mIL-12 and pG.mIL-18, inducing IFN-γ production and cytotoxic T lymphocyte (CTL) and natural killer (NK) activation, in mice B16 melanoma model, this engineered vaccine showed strong tumor suppression (78). This evidence concerns the gene SPRR2A and neoplasm.